SCHEMBL25786834

SCHEMBL25786834

CCn1nc(C)c(-c2ccccc2Nc2cccc(C(F)(F)P)c2)c1C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KCNK18 Q7Z418 1/20 0.38
▸ GAA P10253 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CREBBP Q92793 1/20 0.35
▸ YAP1 P46937 1/20 0.34
▸ TEAD4 Q15561 1/20 0.34
▸ TEAD2 Q15562 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25786811 0.88 KCNK18 (0.35) KCNK18GAAALDH1A1MAPTRAB9A
SCHEMBL25786802 0.86 HTT (0.41) MAPTSMN1; SMN2YAP1TEAD4TEAD2
SCHEMBL25786986 0.82 KCNK18 (0.40) KCNK18GAAALDH1A1MAPTRAB9A
SCHEMBL21749237 0.80 ALDH1A1 (0.44) GAAALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL25786838 0.80 ALDH1A1 (0.46) GAAALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL20553004 0.79 LMNA (0.48) GAAMAPTYAP1TEAD4TEAD2
SCHEMBL25786817 0.78 LMNA (0.47) GAAALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL20553072 0.78 LMNA (0.45) YAP1TEAD4TEAD2LMNARECQL
SCHEMBL20553542 0.70 BRAF (0.41) GAAALDH1A1MAPTRAB9AYAP1
SCHEMBL25786824 0.69 GAA (0.38) GAAALDH1A1MAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 KCNK18 3394/4885GAA 3205/4885ALDH1A1 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback